玻璃体内注射帕尼单抗与近视性黄斑变性
这项单中心、开放标签、多剂量1期研究纳入11例4期近视性黄斑变性患者,玻璃体内注射帕尼单抗0.6mg、1.2mg或1.8mg,间隔2.1至6.3个月。未观察到治疗 emergent 全身不良事件或眼内炎症反应,最佳矫正视力与眼压保持稳定;9例随访超过3个月的患者眼轴长度无显著变化。
要点
- 玻璃体内帕尼单抗最高1.8mg多次注射未出现眼内炎症或全身不良事件。
- 最佳矫正视力(1.62±0.47 logMAR vs 1.28±0.59 logMAR,p=0.08)与眼压(13.8±2.4 mmHg vs 14.3±2.6 mmHg,p=0.20)无显著变化。
- 9例随访超过3个月患者眼轴长度无显著变化(30.73±1.03 mm vs 30.77±1.19 mm,p=0.56)。
核心结论
- 在这项平均随访6.7个月的开放标签1期研究中,玻璃体内重复注射帕尼单抗最高达1.8mg与眼内或全身不良效应无关。
- 研究期间眼轴长度保持不变。
研究设计与样本
- 临床、单中心、开放标签、多剂量1期研究,纳入4期近视性黄斑变性患者,玻璃体内注射帕尼单抗,剂量和间隔不一(间隔范围2.1个月至6.3个月)。
- 共纳入11例患者(年龄66.8±6.3岁),0.6mg组4眼(1眼注射1次、3眼注射2次),1.2mg组4眼(1眼注射1次、2眼注射2次、1眼注射3次),1.8mg组3眼(1眼注射1次、2眼注射2次)。
主要发现
- 无参与者出现治疗 emergent 全身不良事件或眼内炎症反应。
- 最佳矫正视力(1.62±0.47 logMAR vs 1.28±0.59 logMAR;p=0.08)和眼压(13.8±2.4 mmHg vs 14.3±2.6 mmHg;p=0.20)保持不变。
- 9例随访超过3个月(平均6.7±2.7个月)的患者眼轴长度无显著变化(30.73±1.03 mm vs 30.77±1.19 mm;p=0.56)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In experimental studies, intravitreally applied antibodies against epidermal growth factor (EGF), EGF family members (amphiregulin, neuregulin-1, betacellulin, epigen, epiregulin) and against the EGF receptor (EGFR) were associated with a reduction in lens-induced axial elongation and decrease in physiological eye elongation in guinea pigs and in non-human primates. Here, we investigated the intraocular tolerability and safety of a fully human monoclonal IgG2-antibody against EGFR, already in clinical use in oncology, as a potential future therapeutic approach for axial elongation in adult eyes with pathological myopia. METHODS: The clinical, monocentre, open-label, multiple-dose, phase-1 study included patients with myopic macular degeneration of stage 4, who received intravitreal injections of panitumumab in various doses and in intervals ranging between 2.1 months and 6.3 months. RESULTS: The study included 11 patients (age:66.8±6.3 years), receiving panitumumab injections in doses of 0.6 mg (4 eyes; 1×1 injection, 3×2 injections), 1.2 mg (4 eyes; 1×1 injection, 2×2 injections, 1×3 injections) and 1.8 mg (3 eyes; 1×1 injection, 2×2 injections), respectively. None of the participants showed treatment-emergent systemic adverse events or intraocular inflammatory reactions. Best-corrected visual acuity (1.62±0.47 logarithm of the minimal angle of resolution (logMAR) vs 1.28±0.59 logMAR; p=0.08) and intraocular pressure (13.8±2.4 mm Hg vs 14.3±2.6 mm Hg; p=0.20) remained unchanged. In nine patients with a follow-up of >3 months (mean:6.7±2.7 months), axial length did not change significantly (30.73±1.03 mm vs 30.77±1.19 mm; p=0.56). CONCLUSIONS: In this open-labelled, phase-1 study with a mean follow-up of 6.7 months, panitumumab repeatedly administered intravitreally up to a dose of 1.8 mg was not associated with intraocular or systemic adverse effects. During the study period, axial length remained unchanged. TRIAL REGISTRATION NUMBER: DRKS00027302.
引用
- Bikbov MM, Kazakbaeva GM, Holz FG, et al. Intravitreal panitumumab and myopic macular degeneration. Br J Ophthalmol. 2024. PMID: 37429701. doi:10.1136/bjo-2023-323383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。